jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2021-13-1-21-28jofin-1174Research ArticleОбзорReviewВлияние генетических факторов на эффективность, безопасность и переносимость антиретровирусной терапии у больных ВИЧ-инфекциейThe influence of genetic factors on the effectiveness, safety and tolerability of antiretroviral therapy in patients with hiv infectionКанестриВ. Г.KanestriV. G.

Канестри Вероника Геннадиевна – старший научный сотрудник СНИО ЭП СПИД Центрального научно-исследовательского института эпидемиологии; врач-инфекционист Университетской клиники «H-Clinic», д.м.н.

Москвател.: 8(495)366-0518

Moscow

kanestri@yandex.ruШахгильдянВ. И.ShakhgildyanV. I.

Шахгильдян Василий Иосифович – старший научный сотрудник СНИО ЭП СПИД Центрального научно-исследовательского института эпидемиологии, врач-инфекционист Университетской клиники «H-Clinic», к.м.н.

Москва

Moscow

vishakh@yandex.ruКравченкоА. В.KravchenkoA. V.

Кравченко Алексей Викторович – старший научный сотрудник СНИО ЭП СПИД, д.м.н.

Москва

Moscow

alexey-kravtchenko@yandex.ruКонновД. С.KonnovD. S.

Коннов Данила Сергеевич – главный врач Университетской клиники «H-Clinic»; ассистент кафедры инфекционных болезней с курсами эпидемиологии и фтизиатрии медицинского института Российского университета дружбы народов, к.м.н.

Москва

Moscow

kodanila@yandex.ruПоповаА. А.PopovaA. A.

Попова Анна Анатольевна – старший научный сотрудник СНИО ЭП СПИД, к.м.н.

Москва

Moscow

asya-med@mail.ruЦентральный научно-исследовательский институт эпидемиологии; Университетская клиника «H-Clinic»РоссияCentral Research Institute of Epidemiology; University Clinic «H-Clinic»Russian FederationЦентральный научно-исследовательский институт эпидемиологииРоссияCentral Research Institute of EpidemiologyRussian FederationУниверситетская клиника «H-Clinic»; Российский университет дружбы народовРоссияUniversity Clinic «H-Clinic»; Peoples Friendship University of RussiaRussian Federation2021280320211312128Copyright © Канестри В.Г., Шахгильдян В.И., Кравченко А.В., Коннов Д.С., Попова А.А., 20212021Канестри В.Г., Шахгильдян В.И., Кравченко А.В., Коннов Д.С., Попова А.А.Kanestri V.G., Shakhgildyan V.I., Kravchenko A.V., Konnov D.S., Popova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1174

В данной статье представлен обзор существующей литературы по фармакогенетическим детерминантам воздействия и токсичности антиретровирусных препаратов, а также по генетическим маркерам, связанным со скоростью прогрессирования заболевания. Кроме того, рассматриваются текущие возможности в клинической сфере, а также вопросы генетики в разработке лекарств против вируса иммунодефицита человека. Ожидается, что широкомасштабные комплексные подходы к геному в будущем существенно изменят ландшафт знаний.

This article provides an overview of the existing literature on the pharmacogenetic determinants of exposure and toxicity of antiretroviral drugs, as well as on genetic markers associated with the rate of disease progression. In addition, this article looks at current clinical opportunities as well as genetics in HIV drug development. Large-scale, integrated approaches to the genome are expected to significantly change the knowledge landscape in the future.

ВИЧ-инфекцияоппортунистические инфекциисопутствующие заболеваниягенетикаHIV infectioncomorbiditiesgeneticReferencesSánchez A., Cabrera S., Santos D. et al. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients / Antimicrob Agents Chemother, 2011.- V.55 (11).- P.5314-5324Sánchez A., Cabrera S., Santos D. et al. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients / Antimicrob Agents Chemother, 2011.- V.55 (11).- P.5314-5324Rotger M, Colombo S., Furrer H. et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients /Pharmacogenet Genomics, 2005.- V. 15.- P. 1–5Rotger M, Colombo S., Furrer H. et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients /Pharmacogenet Genomics, 2005.- V. 15.- P. 1–5Haas D.W., Ribaudo H.J., Kim R.B., et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study /AIDS, 2004.- V. 18. P.2391–2400Haas D.W., Ribaudo H.J., Kim R.B., et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study /AIDS, 2004.- V. 18. P.2391–2400Haas D.W., Smeaton L.M., Shafer R.W. et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study /J Infect Dis, 2005.- V. 192.- P.1931–1942Haas D.W., Smeaton L.M., Shafer R.W. et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study /J Infect Dis, 2005.- V. 192.- P.1931–1942Fellay J., Marzolini C., Meaden E. R. et al Response to antiretroviral treatment in HIV- 1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study /Lancet, 2002.- V. 359.- P.30–36Fellay J., Marzolini C., Meaden E. R. et al Response to antiretroviral treatment in HIV- 1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study /Lancet, 2002.- V. 359.- P.30–36Lubomirov R1, di Iulio J, Fayet A. Et al ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir /Pharmacogenet Genomics, 2010.- V. 20(4).- P.217-230Lubomirov R1, di Iulio J, Fayet A. Et al ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir /Pharmacogenet Genomics, 2010.- V. 20(4).- P.217-230Rakhmanina N.Y., Neely M.N., Van Schaik R.H. et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children /Ther Drug Monit., 2011.- V. 33(4).- P.417-424Rakhmanina N.Y., Neely M.N., Van Schaik R.H. et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children /Ther Drug Monit., 2011.- V. 33(4).- P.417-424Schuetz J.D., Connelly M.C., Sun D. et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs /Nat Med., 1999.- V. 5.- P. 1048–1051Schuetz J.D., Connelly M.C., Sun D. et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs /Nat Med., 1999.- V. 5.- P. 1048–1051Kwara A., Lartey M., Boamah I. et al. Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian Patients: UGT2B7*1C is Associated with Faster Zidovudine Clearance and Glucuronidation /J Clin Pharmacol., 2009.- V. 49(9).P.1079-1090. doi: 10.1177/0091270009338482Kwara A., Lartey M., Boamah I. et al. Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian Patients: UGT2B7*1C is Associated with Faster Zidovudine Clearance and Glucuronidation /J Clin Pharmacol., 2009.- V. 49(9).P.1079-1090. doi: 10.1177/0091270009338482Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity / AIDS, 1994.- V. 8.- P. 763–769Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity / AIDS, 1994.- V. 8.- P. 763–769Arab-Alameddine M., Fayet-Mello A., Lubomirov R. Et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals /Antimicrob Agents Chemother., 2012.- V. 56(6).- P.2959-2966Arab-Alameddine M., Fayet-Mello A., Lubomirov R. Et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals /Antimicrob Agents Chemother., 2012.- V. 56(6).- P.2959-2966Rotger M., Taffe P., Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia./ J Infect Dis, 2005; V.192(8).- P.1381–1386Rotger M., Taffe P., Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia./ J Infect Dis, 2005; V.192(8).- P.1381–1386Канестри, В.Г. Генетические маркеры клинически выраженных нежелательных явлений у больных ВИЧ-инфекцией, получающих антиретровирусную терапию / В.Г. Канестри [и др.] // ВИЧ-инфекция и иммуносупрессии. – 2014. – Т.6. – №2. – С.49–57Kanestri V.G., Mironov K.O., Kravchenko A.V. i soavt. Geneticheskie markery klinicheski vyrazhennyh nezhelatel’nyh yavlenij u bol’nyh VICh-infekciej, poluchayushchih antiretrovirusnuyu terapiyu /HIV-infekciya i immunosupressii.- 2014.T.6.- №2.- S.49-57Rodríguez-Nóvoa S., Labarga P., D›avolio A. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations / AIDS, 2010.- V. 24(7).- P. 1064-1066Rodríguez-Nóvoa S., Labarga P., D›avolio A. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations / AIDS, 2010.- V. 24(7).- P. 1064-1066Haas D. W., Bartlett J.A., Andersen J. W. et al. Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration / Clinical Infectious Diseases, 2006; V.43.- P.783-786Haas D. W., Bartlett J.A., Andersen J. W. et al. Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration / Clinical Infectious Diseases, 2006; V.43.- P.783-786Chantarangsu S, Mushiroda T, Mahasirimongkol S. et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients / Pharmacogenet Genomics., 2009, V.19 (2).- P.139-146.Chantarangsu S, Mushiroda T, Mahasirimongkol S. et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients / Pharmacogenet Genomics., 2009, V.19 (2).- P.139-146.Kiertiburanakul S., Mahasirimongkol S., Rajatanavin N. et al. HLA-B*3505 and CCHCR1 screening reduces nevirapineassociated cutaneous adverse reactions in Thailand: a prospective multicenter randomized controlled trial. /7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, 2013, Abstract WELBB04Kiertiburanakul S., Mahasirimongkol S., Rajatanavin N. et al. HLA-B*3505 and CCHCR1 screening reduces nevirapineassociated cutaneous adverse reactions in Thailand: a prospective multicenter randomized controlled trial. /7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, 2013, Abstract WELBB04Likanonsakul S., Rattanatham T., Feangvad S. et al. HLACw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients /AIDS Res Ther., 2009.- V. 6.- P. 22–28Likanonsakul S., Rattanatham T., Feangvad S. et al. HLACw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients /AIDS Res Ther., 2009.- V. 6.- P. 22–28Martin A.M., Nolan D., James I. Eeet al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts /AIDS, 2005.- V. 19(1).- P. 97-99.Martin A.M., Nolan D., James I. Eeet al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts /AIDS, 2005.- V. 19(1).- P. 97-99.Vitezica Z.G., Milpied B., Lonjou C. et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz /AIDS, 2008.- V.22.- P.540–541Vitezica Z.G., Milpied B., Lonjou C. et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz /AIDS, 2008.- V.22.- P.540–541Mulherin S.A., O’Brien T.R., Ioannidis J.P., Goedert J.J., Buchbinder S.P., Coutinho R.A., Jamieson B.D., Meyer L., Michael N.L., Pantaleo G., Rizzardi G.P., Schuitemaker H., Sheppard H.W., Theodorou I.D., Vlahov D., Rosenberg P. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. /AIDS, 2003.-V. 17(3).- P. 377-87. doi: 10.1097/01.aids.0000050783.28043.3e.Mulherin S.A., O’Brien T.R., Ioannidis J.P., Goedert J.J., Buchbinder S.P., Coutinho R.A., Jamieson B.D., Meyer L., Michael N.L., Pantaleo G., Rizzardi G.P., Schuitemaker H., Sheppard H.W., Theodorou I.D., Vlahov D., Rosenberg P. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. /AIDS, 2003.-V. 17(3).- P. 377-87. doi: 10.1097/01.aids.0000050783.28043.3e.Инструкция по медицинскому применению препарата абакавир http://www.medicines.org.uk/emc/medicine/15707/SPC/Kivexa+film-coated+tablets/Instrukciya po medicinskomu primeneniyu preparata abakavir http://www.medicines.org.uk/emc/medicine/15707/SPC/Kivexa+film-coated+tablets/Bernasconi E., Boubaker K., Junghans C., et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study /J Acquir Immune Defic Syndr, 2002.- V. 31(1).- P. 50-55Bernasconi E., Boubaker K., Junghans C., et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study /J Acquir Immune Defic Syndr, 2002.- V. 31(1).- P. 50-55Fontas E., van Leth F., Sabin C.A. et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? /J Infect Dis., 2004.- V. 189(6).- P. 1056-1074Fontas E., van Leth F., Sabin C.A. et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? /J Infect Dis., 2004.- V. 189(6).- P. 1056-1074Bastard J.P., Caron M., Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance / Lancet, 2002.- V. 359(9311).- P. 1026-1031Bastard J.P., Caron M., Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance / Lancet, 2002.- V. 359(9311).- P. 1026-1031Mahley R.W., Rall S.C. Jr. Apolipoprotein E: far more than a lipid transport protein /Annu Rev Genomics Hum Genet., 2000.- V.1.- P. 507-537Mahley R.W., Rall S.C. Jr. Apolipoprotein E: far more than a lipid transport protein /Annu Rev Genomics Hum Genet., 2000.- V.1.- P. 507-537Maher B., Alfirevic A., Vilar F.J. et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy /AIDS, 2002.- V.16 (15).- P. 2013-2018Maher B., Alfirevic A., Vilar F.J. et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy /AIDS, 2002.- V.16 (15).- P. 2013-2018Tarr P.E., Taffé P., Bleiber G. et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders /J Infect Dis., 2005.- V. 191 (9).- P. 1419-1426Tarr P.E., Taffé P., Bleiber G. et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders /J Infect Dis., 2005.- V. 191 (9).- P. 1419-1426Egaña-Gorroño L., Martínez E., Cormand B. et al. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy /AIDS, 2013.- V. 27 (4).P. 529-538Egaña-Gorroño L., Martínez E., Cormand B. et al. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy /AIDS, 2013.- V. 27 (4).P. 529-538

The authors declare that there are no conflicts of interest present.